These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15955273)

  • 1. Intravenous Immunoglobulins in MS.
    Stangel M; Gold R
    Int MS J; 2005 Apr; 12(1):5-10, 4. PubMed ID: 15955273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis.
    Dudesek A; Zettl UK
    J Neurol; 2006 Sep; 253 Suppl 5():V50-8. PubMed ID: 16998754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials.
    Sørensen PS
    Neurol Sci; 2003 Oct; 24 Suppl 4():S227-30. PubMed ID: 14598048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis.
    Sorensen PS; Fazekas F; Lee M
    Eur J Neurol; 2002 Nov; 9(6):557-63. PubMed ID: 12453069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous polyclonal human immunoglobulins in multiple sclerosis.
    Soelberg Sorensen P
    Neurodegener Dis; 2008; 5(1):8-15. PubMed ID: 18075269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties.
    Bayry J; Hartung HP; Kaveri SV
    Trends Pharmacol Sci; 2015 Jul; 36(7):419-21. PubMed ID: 26003802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect on MRI of gammaglobulin treatment in relapsing multiple sclerosis.
    Sørensen PS
    Mult Scler; 2000 Oct; 6 Suppl 2():S14-7. PubMed ID: 11188772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [High-dose intravenous immunoglobulins in the treatment of multiple sclerosis. An update].
    Stangel M; Gold R
    Nervenarzt; 2005 Oct; 76(10):1267, 1269-70, 1272. PubMed ID: 15902390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intravenous immunoglobulin in multiple sclerosis].
    Ota K
    Nihon Rinsho; 2003 Aug; 61(8):1374-80. PubMed ID: 12962026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immune globulin in multiple sclerosis: clinical and neuroradiological results and implications for possible mechanisms of action.
    Achiron A; Barak Y; Goren M; Gabbay U; Miron S; Rotstein Z; Noy S; Sarova-Pinhas I
    Clin Exp Immunol; 1996 May; 104 Suppl 1():67-70. PubMed ID: 8625547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.
    Hommes OR; Sørensen PS; Fazekas F; Enriquez MM; Koelmel HW; Fernandez O; Pozzilli C; O'Connor P
    Lancet; 2004 Sep 25-Oct 1; 364(9440):1149-56. PubMed ID: 15451222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intravenous immunoglobulins (IVIg) in the treatment of multiple sclerosis].
    Achiron A; Miron S
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S41-4. PubMed ID: 10896988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of intravenous immunoglobulin in the treatment of multiple sclerosis.
    Sorensen PS
    J Neurol Sci; 2003 Feb; 206(2):123-30. PubMed ID: 12559498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.
    Visser LH; Beekman R; Tijssen CC; Uitdehaag BM; Lee ML; Movig KL; Lenderink AW
    Mult Scler; 2004 Feb; 10(1):89-91. PubMed ID: 14760960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Austrian Immunoglobulin in MS (AIMS) study: final analysis.
    Strasser-Fuchs S; Fazekas F; Deisenhammer F; Nahler G; Mamoli B
    Mult Scler; 2000 Oct; 6 Suppl 2():S9-13. PubMed ID: 11188778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results.
    Sørensen PS; Wanscher B; Schreiber K; Blinkenberg M; Jensen CV; Ravnborg M
    Mult Scler; 1997 Apr; 3(2):145-8. PubMed ID: 9291170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.
    Achiron A; Kishner I; Sarova-Pinhas I; Raz H; Faibel M; Stern Y; Lavie M; Gurevich M; Dolev M; Magalashvili D; Barak Y
    Arch Neurol; 2004 Oct; 61(10):1515-20. PubMed ID: 15477504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous immunoglobulin in MS: promise or failure?
    Fazekas F; Strasser-Fuchs S; Hommes OR
    J Neurol Sci; 2007 Aug; 259(1-2):61-6. PubMed ID: 17449063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.
    Humle Jorgensen S; Sorensen PS
    J Neurol Sci; 2005 Jun; 233(1-2):61-5. PubMed ID: 15949496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.